OSBP-related protein-2 (ORP2): a novel Akt effector that controls cellular energy metabolism by Kentala, Henriikka et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/112275/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Kentala, Henriikka, Koponen, Annika, Vihinen, Helena, Pirhonen, Juho, Pirhonen, Juho, Liebisch,
Gerhard, Pataj, Zoltan, Kivelä, Annukka, Li, Shiqian, Karhinen, Leena, Jääskeläinen, Eeva,
Andrews, Robert, Meriläinen, Leena, Matysik, Silke, Ikonen, Elina, Zhou, You, Jokitalo, Eija and
Olkkonen, Vesa M. 2018. OSBP-related protein-2 (ORP2): a novel Akt effector that controls
cellular energy metabolism. Cellular and Molecular Life Sciences 75 (21) , pp. 4041-4057. file 
Publishers page: http://dx.doi.org/10.1007/s00018-018-2850-8 <http://dx.doi.org/10.1007/s00018-
018-2850-8>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 1 
OSBP-related protein-2 (ORP2): A novel Akt effector that controls 
cellular energy metabolism 
Henriikka Kentalaa, Annika Koponena, Helena Vihinenb, Juho Pirhonena,c, Gerhard 
Liebischd, Zoltan Patajd, Annukka Kiveläa, Shiqian Lia,c, Leena Karhinenc, Eeva 
Jääskeläinena, Robert Andrewse, Leena Meriläinenb, Silke Matysikd, Elina Ikonena,c, You 
Zhoua,e,f , Eija Jokitalob, and Vesa M. Olkkonena,c* 
aMinerva Foundation Institute for Medical Research, FI-00290 Helsinki, Finland  
bElectron Microscopy Unit, Institute of Biotechnology, FI-00014 University of Helsinki, 
Helsinki, Finland 
cDepartment of Anatomy, Faculty of Medicine, FI-00014 University of Helsinki, Finland 
dInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital 
Regensburg, D-93053 Regensburg, Germany 
eSystems Immunity Research Institute, Cardiff University, Cardiff, CF14 4XN, UK  
fDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, 
CF14 4XN, UK 
 
*Corresponding author. Minerva Foundation Institute for Medical Research, Biomedicum 
2U, Tukholmankatu 8, FI-00290 Helsinki, Finland. E-mail: vesa.olkkonen@helsinki.fi 
(V.M. Olkkonen) 
Abbreviations 
CRISPR clustered regularly interspaced short palindromic repeats 
ECAR  extracellular acidification rate 
EM  electron microscopy 
ER  endoplasmic reticulum 
FA  fatty acid 
GSK  glycogen synthase kinase 
HUVEC human umbilical vein endothelial cell 
IPA  Ingenuity pathway analysis 
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LD  lipid droplet 
LDL  low-density lipoprotein 
OSBP  oxysterol-binding protein 
ORP  OSBP-related protein 
PIP  phosphatidylinositol phosphate 
TEM  transmission electron microscopy 
TG  triacylglycerol 
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Abstract 
ORP2 is a ubiquitously expressed OSBP-related protein previously implicated in 
endoplasmic reticulum (ER)  lipid droplet (LD) contacts, triacylglycerol (TG) 
metabolism, cholesterol transport, adrenocortical steroidogenesis, and actin-dependent 
cell dynamics. Here, we characterize the role of ORP2 in carbohydrate and lipid 
metabolism by employing ORP2-knock-out (KO) hepatoma cells (HuH7) generated by 
CRISPR-Cas9 gene editing. The ORP2-KO and control HuH7 cells were subjected to 
RNA sequencing, analyses of Akt signaling, carbohydrate and TG metabolism, the 
extracellular acidification rate, and the lipidome, as well as to transmission electron 
microscopy. 
  The loss of ORP2 resulted in a marked reduction of active phosphorylated 
Akt(Ser473) and its target Glycogen synthase kinase 3E(Ser9), consistent with defective 
Akt signaling. ORP2 was found to form a physical complex with the key controllers of 
Akt activity, Cdc37 and Hsp90, and to co-localize with Cdc37 and active Akt(Ser473) at 
lamellipodial plasma membrane regions, in addition to the previously reported ER–LD 
localization. ORP2-KO reduced glucose uptake, glycogen synthesis, glycolysis, mRNAs 
encoding glycolytic enzymes, and SREBP-1 target gene expression, and led to defective 
TG synthesis and storage. ORP2-KO did not reduce but rather increased ER–LD contacts 
under basal culture conditions but interfered with their expansion upon fatty acid loading.  
 Together with our recently published work (Kentala et al., FASEB J 2017, Nov 1. 
PMID: 29092904), this study identifies ORP2 as a new regulatory nexus of Akt signaling, 
cellular energy metabolism, actin cytoskeletal function, cell migration and proliferation.  
 
Keywords Akt signaling; CRISPR-Cas9; glycolysis; OSBPL2; OSBP-related protein; 
triacylglycerol 
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Introduction 
 
Oxysterol binding protein (OSBP)-related protein 2 (ORP2) belongs to a conserved 
family of ubiquitous lipid-binding/transfer proteins, characterized by a carboxy-terminal 
OSBP-related lipid-binding domain (ORD). In addition, most ORPs contain an amino-
terminal pleckstrin homology (PH) domain that binds membrane phosphoinositides 
(PIPs) and a two phenylalanines in an acidic tract (FFAT) motif which targets the ORPs 
to the ER membranes via interaction with the the integral VAMP-associated proteins 
(VAPs) [28, 37]. The ORD of several ORPs binds cholesterol, oxysterols, or 
phosphatidylserine (PS) and additionally PI4P or other PIPs [8, 11, 17, 30, 31, 34, 48]. 
Recent hallmark studies have established that a number of ORPs have the capacity to 
mediate the counter-current transport of cholesterol or PS in exchange for PIPs, a process 
in which the synthesis and hydrolysis of PIPs energizes the transport of cholesterol or PS 
against their concentration gradients [8, 31, 32, 34]. For the founder member of the ORP 
family, OSBP, it was shown that its highest-affinity oxysterol ligand, 25-
hydroxycholesterol (25OHC) inhibits the function of the protein as a bidirectional 
cholesterol/PI4P transporter at ER-Golgi contacts [31]. 
 ORP2 is a cytosolic protein which lacks the membrane-targeting PH domain but is found 
to transiently localize on the surface of the intracellular lipid droplets and to ER–LD 
contacts [16, 22]. In cells lacking large lipid droplets or after treatment with the high-
affinity oxysterol ligand of ORP2, 22(R)-hydroxycholesterol [22(R)OHC], the protein is 
often found in the cortical region of the cells [16, 22]. The cellular function of ORP2 was 
previously linked to cholesterol and triacylglycerol (TG) homeostasis. ORP2 is found to 
bind cholesterol, 22(R)OHC, 25OHC and 7-ketocholesterol (7KC) [16, 47]. Furthermore, 
ORP2 was reported to bind lipid vesicles containing phosphatidylinositol phosphates 
(PIPs) [15]. In HeLa cells ORP2 overexpression was shown to increase the efflux of 
[14C]cholesterol and enhance its intracellular transport [15]. In adrenocortical cells, 
silencing of ORP2 was shown to increase the levels of cholesterol and to reduce 
22(R)OHC and 7KC [12]. Knock-down of ORP2 and its ER anchors, the VAP proteins in 
HuH7 hepatoma cells was found to enhance the hydrolysis and to decrease the synthesis 
of [3H]TGs [50].   
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 Our recently published observations revealed a cellular role for ORP2 beyond 
lipid metabolism. Analysis of ORP2 knock-out (ORP2-KO) HuH7 cells indicated a role 
for ORP2, in addition to lipid metabolism, in actin cytoskeletal regulation as well as in 
the control of cell adhesion, migration and proliferation [21]. Moreover, analysis of 
ORP2 protein interactome in HuH7 cells identified ORP2 binding partners involved in 
RhoA signaling [21], a central actin regulatory pathway. These findings prompted the 
hypothesis that ORP2 could mediate a crosstalk between lipid metabolism and actin 
cytoskeletal functions. In the present study we demonstrate a defect in Akt signaling and 
analyze the energy metabolism and lipidome in HuH7 hepatoma cells subjected to ORP2-
KO by CRISPR-Cas9 mediated gene editing. 
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Experimental procedures 
Antibodies           
The rabbit anti-ORP2 antibody was described in [24]. Anti-β-actin was purchased from 
Sigma–Aldrich (St. Louis, MO). Rabbit anti-Cdc37, anti-Hsp90, anti-Akt, anti-
Akt(Ser473), anti-GSK-3β and anti-GSK-3β(Serλ) were from Cell Signaling (Danvers, 
MA). Mouse monoclonal anti-Cdc37 was from Thermo Scientific (Waltham, MA) and 
mouse monoclonal anti-cortactin from Merck-Millipore (Temecula, CA). The fluorescent 
secondary fAlexa Fluor-568 goat anti-rabbit and Cy5® goat anti-mouse antibodies were 
from Molecular Probes/Invitrogen (Carlsbad, CA) and Life Technologies (Eugene, OR), 
respectively. 
 
Cell culture, ORP2-KO cell lines, and transfections      
The HuH7 human hepatoma cell line [35] was cultured as described in [21, 22]. ORP2-
KO lines were derived therefrom by CRISPR-Cas9-mediated gene editing by employing 
vectors described in [42, 44] as reported in [21]. For the generation of ORP2-KO1 guide 
RNAs targeting exon 4 of OSBPL2 were used and for ORP2-KO2 guide RNAs targeting 
both exon 4 and 5 were used. The Cas9 control HuH7 cells were prepared similarly to the 
KO cells transfected with the Cas9 expression plasmid without the OSBPL2-specific 
gRNA constructs. HuH7 cells were transfected with a GFP-ORP2 (human ORP2 cDNA 
in pEGFP-N1, Clontech/TaKaRa Bio, Mountain View, CA) using Lipofectamine® 2000 
(Invitrogen). Human umbilical vein endothelial cells (HUVECs; Lonza, Basel, 
Switzerland) were cultured in fibronectin-gelatin coated flasks in endothelial cell growth 
medium [EGM; 0.1% human epidermal growth factor (EGF), 0.1% hydrocortisone, 0.1% 
Gentamicin-Amphotericin-B, 0.4% bovine brain extract, 2% foetal bovine serum; Lonza], 
and transfected by electroporation by using the Nucleofector® Kit for HUVECs (Lonza). 
 
Lentivirus-mediated ORP2 overexpression and knock-down 
Generation of recombinant lentiviruses expressing wild-type (wt) ORP2 or its mutants 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
ORP2 mPIP (H178–179A, K423A) and mFFAT (F7–8V, D9V), and a GFP-encoding 
vector control, as well as cell infections of ORP2-KO HuH7 cells are described in [21]. 
Knock-down of ORP2 in HUVECs was carried out by transducing the cells for 48 h at a 
multiplicity of infection 10, with an lentivirus expressing the ORP2-specific shRNA, 
TRCN0000154381 (Sigma-Aldrich), by using non-targeting SHC002 (Sigma-Aldrich) as 
a control. The viruses were packaged and titrated by the Virus Core of the Biomedicum 
Functional Genomics Unit (Helsinki Institute of Life Science, HiLIFE). 
 
RNA sequencing and pathway analysis 
RNA sequencing was performed as described in [21]. In detail, samples were prepared 
from 4 parallel basal cultures each of ORP2-KO1, ORP2-KO2 and Cas9 control HuH7 
cells using TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero (Illumina, San 
Diego, CA). BWA [26]was used to align output reads to human reference genome 
(GRCh38). The FeatureCounts program [27] was employed to count mapped fragments 
against genomic features defined by the Ensembl annotation file 
(Homo_sapiens.GRCh38.76.gtf). The genes with counts equal or less than 1 in all 
samples were removed and Deseq2 was used to analyse the differential gene expression 
[29]. Benjamini-Hochberg test was used to control the false discovery rate. Genes which 
differed significantly (adjusted p-value < 0.05) between ORP2-KO1 and Cas9 control 
cells were selected for analysis by Ingenuity Pathways Analysis® tool (IPA, 
www.ingenuity.com). Enrichment of the genes in the pathways was assessed in 
comparison with a reference set in the whole Ingenuity pathway knowledge base.  
 
Western blotting 
Western blot analyses were carried out as described in [50]. 
 
Pull-down assay 
HuH7 cells were grown in basal culture conditions or alternatively treated with 5 µM 
Withaferin A for 24 h prior to lysis in 10 mM HEPES pH 7.6, 150 mM NaCl, 0.5 mM 
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 8 
MgCl2, 10 % glycerol, 0.5 % Triton X-100, 0.5 % Na-deoxycholate, Protease inhibitor 
cocktail (Roche Diagnostics, Basel, Switzerland). Lysates were mixed thoroughly by 
vortexing and incubated on ice for 10 min. Unbroken cells and insoluble material were 
removed by 10 min centrifugation at 20,000 x g. The obtained lysates were incubated 
with 300 µmol GST-ORP2 or GST [21] and 20 µl Glutathione-Sepharose 4B (GE 
Healthcare, Buckinghamshire, UK) for 2 h at 4 °C. The beads were washed four times 
with the lysis buffer, resuspended in 30 µl Laemmli sample buffer, boiled for 5 min, and 
separated by SDS-PAGE. The bound proteins were detected on western blots with anti-
Cdc37, anti-Akt, and anti-Hsp90 antibodies. 
 To study the role of Akt phosphorylation, cell lysates containing 0.1 mg of total 
protein were treated with 2000 U of Lambda protein Phosphatase (Ȝ-PP, New England 
BioLabs, Ipswich, MA) in 50 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM DTT, 0.01% 
Brij 35, 1 mM MnCl2  and Protease inhibitor cocktail (Roche Diagnostics) for 1 h at 30°C, 
followed by pull-down assay with GST-ORP2 as described above. 
 
Immunofluorescence staining 
HuH7 cells were fixed with 4% paraformaldehyde, 0.02% glutaraldehyde in phosphate 
buffered saline (PBS) for 30 min. Aldehyde groups were blocked with 50 mM NH4Cl for 
15 min and cells were permeabilized with 0.1% Triton X-100 for 5 min. Unspecific 
binding of antibodies was blocked with 10% FBS for 45 min, followed by incubation 
with the primary antibodies in 5% FBS for 30 min at 37° C. The cells were washed with 
PBS, incubated with fluorescent secondary antibodies in 5% FBS for 45 min at 37° C, 
and mounted in a mixture of Mowiol (Calbiochem, La Jolla, CA), 1,4-Diazabicyclo-
[2.2.2]octane (50 mg/ml, Sigma-Aldrich), and DAPI (5 ȝg/ml, Molecular Probes). 
 
Fluorescence microscopy         
Fluorescence signals were detected with a Zeiss Axio Observer Z1 microscope with a 
PlnApo 63x/1.40 oil DICII objective and Colibri laser. Images were recorded with the 
Zen 2 2.0.0 software (Carl Zeiss Imaging Solutions GmbH, Oberkochen, Germany).  
Image panels were created with Adobe Photoshop7 software. 
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Assays for glucose and fatty acid uptake 
Glucose uptake was measured in ORP2-KO and Cas9 control cells after starving the cells 
in glucose and serum free Dulbecco’s modified Eagle medium (DMEM, Gibco, Grand 
Island, NY) for 3 h. The cells were treated with a mixture of 10 µM 2-Deoxy-D-glucose 
(Sigma-Aldrich) and 10 µM [3H]-2-deoxy-D-glucose (100 mCi/mmol) (PerkinElmer, 
Waltham, MA) for 15 min. The non-specific uptake of glucose was measured by treating 
the cells 45 min with 40 µM Cytochalasin B (Sigma-Aldrich) prior to adding the glucose 
mixture. The cells were washed three times with PBS and lysed in 0.03% SDS. The 
radioactivity of the lysed cells was measured by liquid scintillation counting in Optiphase 
HiSafe 3 scintillation cocktail (PerkinElmer) and normalized to total cellular protein 
(BCA assay, Thermo Scientific). The non-specific glucose uptake was subtracted from 
the measurements. 
 Fatty acid uptake was measured similarly: ORP2-KO and Cas9 control were 
starved in glucose and serum free DMEM for 3 h, followed by treatment with a mixture 
of 20 mM glucose, 5 nM oleic acid-BSA and 1 µCi [3H]-oleic acid (PerkinElmer) for 15 
min. The cell lysis and scintillation counting were performed as described above. 
 
Assay for glycogen synthesis 
To measure glycogen synthesis, cells were first starved for 2 h in glucose and serum free 
DMEM (Gibco). The cells were then treated with 0.18 µCi/µmol D-[U-14C]-glucose 
(PerkinElmer) for 1 h, after which they were washed three times with PBS and lysed in 
0.03% SDS. The extracted glycogen was mixed with 1 mg carrier glycogen (Sigma-
Aldrich) and boiled for 30 min, followed by precipitation with 98–99% ethanol. The 
precipitated glycogen was washed with 70% ethanol, centrifuged at 20,000 x g for 15 min 
and dried from the excess ethanol. The radioactivity of the glycogen was measured with 
liquid scintillation counting in Optiphase HiSafe 3 scintillation cocktail (PerkinElmer) 
and normalized to total cellular protein (BCA assay, Thermo Scientific). 
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Determination of glycolytic activity 
To analyze glycolysis, ORP2-KO and Cas9 control cells were seeded on XF96 cell 
culture microplates in basal growth medium (Agilent Tecnologies, Santa Clara, CA). 
After 24 h, the culture media was changed to Seahorse XF base medium (Agilent 
Tecnologies) with 2 mM L-glutamine (pH 7.35) and incubated for 1 h at 37°C in a non-
CO2 incubator. After incubation, extracellular acidification rate (ECAR) was measured in 
real time with a Seahorse XFe96 Analyzer (Agilent Technologies) as follows: cells were 
treated with 10 mM glucose, 1 ȝM Oligomycin and 50 mM 2-Deoxy-D-glucose (Sigma-
Aldrich) followed by a 20 min measurement between the treatments. Extracellular 
acidification was normalized to total cellular protein. Glycolysis was calculated by 
subtracting the non-glycolytic ECAR from the maximum ECAR after glucose injection. 
 
Analysis of cellular TG content and TG synthesis      
Thin-layer chromatography used to analyze the TG content of HuH7 ORP2-KO and Cas9 
control cells is described in [16, 22] and the radiometric method to analyze TG synthesis 
in [16]. 
 
Lipidome analysis        
Methodology of the mass spectrometric lipidome analysis is described in the 
Supplementary Materials. 
 
Transmission electron microscopy and quantification of LDs and ER–LD contacts 
For TEM analysis, cells grown on glass coverslips were fixed, osmicated, dehydrated in a 
graded ethanol series and acetone, and infiltrated into Epon (TAAB, Aldermaston, United 
Kingdom) as described by [41]. 60-nm thick sections were cut parallel to the cover slip, 
and post-stained with uranyl acetate and lead citrate. Specimens were observed using Jeol 
JEM 1400 (Jeol Ltd., Tokyo, Japan) microscope equipped with Orius SC 1000B bottom 
mounted CCD camera (Gatan Inc., USA) at acceleration voltage of 80 kV. For systematic 
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random sampling sixteen cells from each condition were selected at low magnification 
and four non-overlapping images were acquired from the cell cytoplasmic area at 
nominal magnification of 6000 x. To analyze LDs and ER–LD contact sites, all complete 
LDs and the adjacent ER in the TEM micrographs were manually traced using MIB 
software [4] and the quantity and the length of ER–LD contacts sites were analyzed using 
a custom made plugin in MIB. The probing distance of 150 nm between the ER and LDs 
was applied and the profiles closer than 30 nm were assigned as a contact site. 
 
 Statistics 
In the IPA analysis, Fisher's exact test was used to determine the significance of each 
pathway and the Benjamini–Hochberg method was used to control for false discovery 
rate. Statistical analysis of TLC data and cell biological assays was carried out by using 
Student’s T-test (two-tailed, independent). 
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Results  
 
ORP2-KO interferes with Akt signaling         
RNA sequencing analysis of HuH7 hepatoma cells subjected to ORP2 knock-out by 
CRISPR-Cas9 gene editing [21] identified 20 components of the PI3K/Akt signaling 
pathway dysregulated in the ORP2-KO cells (Fig. 1A,B). Nine of the mRNAs were up-
regulated (Fig. 1A, shown in green; Fig. 1B) and 11 down-regulated (Fig. 1A, shown in 
red; Fig. 1B). Ingenuity® pathway analysis of the mRNAs affected by ORP2-KO 
predicted PI3K/Akt signaling to be significantly inhibited (activation z-score -1.7, p-
value of overlapping genes 0.03). Prompted by these observations, the activity of the Akt 
signaling pathway in the two previously characterized ORP2-KO cell lines (ORP2-KO1 
and -2; [21]) and Cas9 control cells was studied by western analysis with phosphor-
Akt(Ser473) and glycogen synthase kinase 3β [GSK-3β(Serλ)] antibodies. The cells were 
either serum starved for 2 h (Fig. 1A) or grown in the basal culture medium (Fig. 1B), in 
the absence or presence of 8 min stimulation with 100 nM insulin, prior to lysis and 
sample preparation. The levels of Akt(Ser473) or GSK-3β(Serλ) were normalized to the 
total Akt and GSK-3β signals. The analysis revealed significant inhibition in the 
phosphorylation of Akt (Fig. 2C) and GSK-3β (Fig. 2D), under both basal and insulin-
stimulated conditions [by 35–73% and 30–36%, respectively], indicating a suppression of 
PI3K/Akt signaling in the ORP2-KO cells. 
To confirm the effect of ORP2 depletion on Akt(Ser473) phosphorylation also in non-
cancerous cells, we subjected primary human umbilical vein endothelial cells (HUVECs) 
to ORP2 knock-down with a lentivirus expressing ORP2-specific shRNA. In these cells, 
a similar dampening of Akt activation (-65%) upon epidermal growth factor (EGF) 
stimulation as in the HuH7 model, was observed (Fig. 2E). Furthermore, to assess 
whether the Akt phosphorylation defect is directly caused by the lack of ORP2, we 
overexpressed wild type (wt) ORP2 or its mutants defective in binding the ER receptors, 
VAPs (mFFAT), or phosphoinositides (mPIP) in the basally cultured HUVECs with a 
lentiviral vector, followed by western analysis of Akt(Ser473) phosphorylation. In these 
experiments the wt ORP2 but also both of the mutants were capable of enhancing the 
phosphorylation of Akt. The effect of ORP2(mFFAT) was weaker than of the wt and 
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mPIP proteins, but this may be due to the lower expression level (or reduced stability) of 
the mFFAT protein (Supplemental Fig. S1A).     
  
ORP2 interacts with the Akt effectors Cdc37 and Hsp90     
We previously identified the ORP2 interactome in HuH7 cells by a co-
immunoprecipitation approach [21]. Interestingly, the Akt effector heat shock protein 90 
(Hsp90) co-chaperone Cdc37 was identified in this analysis as a specific partner of ORP2. 
We now validated the interaction of ORP2 with endogenous Cdc37 by pull-down assays 
using recombinant GST-ORP2 and lysates of HuH7 cells. The GST-ORP2 pull-downs 
contained abundant Cdc37, while the negative controls with plain GST lacked the signal 
(Fig. 2F), supporting a specific interaction of Cdc37 with ORP2. To clarify whether 
ORP2 is physically associated with the Akt signaling activating protein complex Hsp90–
Cdc37–Akt, the pull-down fractions were probed with anti-Akt and anti-Hsp90 
antibodies. Interestingly, the analysis revealed specific signals in the GST-ORP2 pull-
downs for both Akt and Hsp90 (Fig. 2F), suggesting that ORP2 may interact with the 
Hsp90–Cdc37–Akt complex. Of note, the ORP2 interactome [21] contained, in addition 
to Cdc37, also other established Hsp90-associated proteins: FK506-binding protein 4 
(FKBP52) [38] and nuclear autoantigen sperm protein (NASP) [1].     
 To further analyze the specificity of ORP2 interaction with the Hsp90–Cdc37–
Akt complex, cells were treated with 5 ȝM Withaferin A for 24 h prior to the pull down 
assays. Withaferin A is a steroidal lactone which has previously been shown to bind 
Hsp90, inhibiting its interaction with Cdc37 and hence its chaperone activity. Thereby, 
this drug reduces the phosphorylation and enhances the degradation of Akt [55]. In our 
pull-down assays the Withaferin A treatment did not disrupt the interaction of ORP2 with 
Hsp90 or Cdc37 (Fig. 2G), bringing up the possibility that ORP2 may interact directly 
with both of these proteins. The Withaferin A treatment did, however, drastically reduce 
the phosphorylation of Akt, evident from an Akt mobility shift. We confirmed that this 
shift truly reflects loss of Akt phosphorylation by dephosphorylation of Akt with lambda 
protein phosphatase before the SDS-PAGE/western analysis (Fig. 2H). Moreover, GST-
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ORP2 was only able to pull down the lower mobility, hyperphosphorylated active form of 
Akt and the interaction was abolished upon dephosphorylation with lambda phosphatase 
(Fig. 2H), supporting a functional role of ORP2 in the protein complex that promotes Akt 
activation. 
 
ORP2 colocalizes with Cdc37 and phosphorylated Akt at lamellipodia 
To visualize the distribution of ORP2, Cdc37 and active Akt, cells transfected with 
ORP2-GFP were after insulin stimulation stained for the endogenous Cdc37 and 
Akt(Ser473) (Supplemental Fig. S2). Since HuH7 cells are not particularly amenable to 
morphologic observation, these studies were also carried out in HUVECs (Fig. 3). 
Interestingly, ORP2 was found to co-localize with both Cdc37 and Akt(Ser473) at 
specific regions of the cell surface, which were by cortactin staining shown to represent 
actively expanding lamellipodia (Fig. 3A,B; Supplemental Fig. S2). Of note, we recently 
showed that a defect in lamellipodia formation is a hallmark phenotype of the ORP2-KO 
cells, resulting in decreased cell motility [21]. We have previously reported prominent 
localization of ORP2 at the surface of cytoplasmic lipid droplets or at ER domains that 
associate with LD surfaces [16, 22, 50]. The lamellipodial localization is easily 
overlooked in cells that display intense ORP2 staining at the LD. Moreover, in cells 
treated with the high-affinity oxysterol ligand of ORP2, 22(R)hydroxycholesterol [16, 22], 
or in ones that do not have large LDs, the emphasis of ORP2 localization is frequently 
seen at the cell cortex. To analyse whether the lamellipodial localization is dependent of 
interaction of ORP2 with VAPs, an ORP2 mutant incapable of VAP-binding (mFFAT) 
was overexpressed in HUVECs and the lamellipodia were visualized with cortactin 
staining. Similar to wt ORP2, the ORP2(mFFAT) co-localized with cortactin at 
lamellipodial cell surface protrusions, indicating that the interaction of ORP2 with the ER 
is not essential for its lamellipodial localization (Fig. 3C).  
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ORP2 knock-out reduces glucose uptake and glycogen synthesis 
The Akt serine/threonine kinase plays a key role in the regulation of glucose homeostasis 
by elevating glucose uptake and increasing glycogen synthesis via phosphorylation of 
GSK-3 [9]. The results outlined in 3.1. demonstrated that the loss of ORP2 suppresses 
Akt signaling with possible effects on cellular carbohydrate metabolism. In addition, the 
ORP2-KO cells’ transcriptome and IPA analyses indicated a close link between ORP2 
and carbohydrate metabolism (p-value of overlapping genes 0.018). Therefore, the 
capacity of ORP2-KO cells to take up glucose was measured by incubating glucose- and 
serum-starved cells with [3H]-2-deoxy-D-glucose for 15 min, followed by measurement 
of the cellular radioactivity. The analysis demonstrated that the glucose uptake was 
reduced by 28–33% in the ORP2-KO cells as compared to the controls (Fig. 4A).    
 To further characterize the intracellular handling of glucose, the incorporation of 
D-[U-14C]-glucose into glycogen during 1 h was analyzed in ORP2-KO and control cells. 
The synthesis of glycogen in ORP2-KO cells was reduced by 50–58 % as compared to 
the control (Fig. 4B), fully consistent with the observed reduction of GSK-3β(Serλ) 
phosphorylation. We next re-expressed ORP2 in the KO cells by using a lentiviral vector 
to determine if this can rescue the defect in glycogen synthesis. The expression of ORP2 
elevated glycogen synthesis in these cells by 37% as compared to the mock-transfected 
KO control (Fig. 4C), confirming that the synthesis defect is truly due to the loss of 
ORP2. In order to study whether the interactions of ORP2 with VAPs or 
phosphoinositides are necessary for this rescue effect, we also re-expressed the mFFAT 
and mPIP mutants of ORP2 in the KO cells, followed by analyses of glycogen synthesis. 
The results revealed that ORP2(mFFAT) rescued the glycogen synthesis, whereas the 
effect of ORP2(mPIP) varied between experiments, with no statistically significant 
overall rescue effect detectable (Supplemental Fig. S1B). These observations suggest that 
the binding of VAPs may be dispensable for the function of ORP2 in glucose metabolism, 
while the functional significance of PIP binding cannot be reliably inferred from the 
present data. 
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ORP2-KO inhibits glycolysis 
The RNA sequencing demonstrated that the loss of ORP2 results in down-regulation of 
12 major glycolytic genes, glycolysis being indicated as a significantly affected function 
by the IPA analysis of the ORP2-KO cells (p-value of overlapping genes 0.003; Fig. 
4D,E). The glycolytic capacity of ORP2-KO and control cells was therefore measured 
with a Seahorse® XFe96 extracellular flux analyser by monitoring their extracellular 
acidification rate in the presence of glucose substrate (Fig. 4F). Consistent with the 
suppression of major glycolytic genes, the rate of glycolysis was in the ORP2-KO cells 
reduced by 22–37% as compared to the controls (Fig. 4G). 
 
Knock-out of ORP2 reduces the cellular triacylglycerol content 
Prompted by our earlier observations on impacts of ORP2 knock-down on cellular TG 
metabolism [16, 50], we investigated the TG content of ORP2-KO and Cas9 control cells 
under basal culture conditions by thin-layer chromatography. The analysis revealed a 
significant, 21–28% reduction of the cellular TGs in the ORP2-KO cells as compared to 
the controls (Fig. 5A). The capacity of ORP2-KO and control cells to synthesize TGs was 
measured by [3H]-oleic acid labeling during a 3 h period. TG synthesis by the KO cells 
was reduced by 41–53 % as compared to the controls (Fig. 5B). Of note, fatty acid uptake 
measured by incubating the cells with [3H]-palmitic acid did not differ between the 
ORP2-KO and the controls (Fig. 5C), consistent with a defect in the activation or 
incorporation of fatty acids into TGs. We next re-expressed ORP2 in the KO cells with a 
lentiviral vector and measured the effect on TG synthesis as above. The re-expression of 
ORP2 increased the TG synthesis by 31 % as compared to the mock-transfected KO 
control (Fig. 5D), demonstrating that the TG synthesis defect results from the loss of 
ORP2. However, no significant difference between the TG synthesis rescue with the wt 
ORP2 and ORP2 mutants mFFAT and mPIP was detected (Supplemental Fig. S1C), 
suggesting that the ORP2 TG metabolic function is not directly dependent on ORP2’s 
ability to bind VAP or PIPs.  
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ORP2 knock-out modulates the expression of SREBP-1 and TG metabolic genes 
The cellular TGs are retained within intracellular lipid droplets (LD), which store energy 
in the form of neutral lipids. The balance between TG synthesis and hydrolysis is 
coordinated to respond to the fluctuating energy demands of the cell. One master 
regulator of TG homeostasis is the transcription factor Sterol regulatory element-binding 
protein-1, SREBP-1 [14]. To obtain clues of the mechanisms underlying the phenotypic 
effects of ORP2-KO, we again analyzed the transcriptome data of these cells [21]. 
 When the mRNAs dysregulated in the ORP2-KO cells were compared to known 
SREBP-1 target genes [43], 27 established SREBP-1 targets were found to be 
significantly affected by the ORP2-KO (Fig. 5E). Moreover, we compared the mRNAs 
affected by ORP2-KO with the list of gene promoters occupied by SREBP-1 in a global 
chromatin immunoprecipitation analysis [43]. This comparison revealed 168 genes the 
promoters of which are occupied by SREBP-1 and which are affected by the loss of 
ORP2 (Supplemental Table S1). IPA analysis of the mRNAs affected by ORP2-KO 
predicted SREBP-1 transcriptional regulation to be significantly inhibited (activation z-
score -2.2, p-value of overlapping genes 0.0001). This suggests that the observed 
reduction in the TG content of ORP2-KO cells is at least in part due to a suppression of 
SREBP-1 function. In addition to the SREBP-1 targets, we identified among the genes 
affected by ORP2-KO 11 other mRNAs with established roles in TG metabolism (Fig. 
5F). The above results imply that the depletion of cellular TGs by ORP2-KO involves 
disturbed transcriptional regulation of multiple TG homeostatic genes.  
 
ORP2-KO does not reduce the quantity of ER–LD contacts but alters their dynamics 
upon fatty acyl loading   
ORP2 was previously found to localize on the surface of intracellular LDs or at ER–LD 
membrane contact sites [16, 22]. To investigate whether the loss of ORP2 affects the 
extent of ER–LD contacts, we analyzed by TEM the ORP2-KO cell lines and Cas9 
control cells grown under basal conditions or after 3 h fatty acid loading (Fig. 6A). Upon 
fatty acid loading, the total LD area increased significantly in Cas9 control and ORP2-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
KO1, the increase being minor and insignificant in ORP2-KO2 (Fig. 6B). However, the 
total length of ER–LD contacts was only significantly increased in Cas9 control cells 
upon FA loading, but did not change in ORP2-KO cells. Of note, the length of ER–LD 
contacts was significantly elevated in ORP2-KO cells under basal conditions compared to 
Cas9 controls (Fig. 6C). These observations demonstrated that ORP2 is not essential for 
the formation of ER–LD contacts nor the growth of LD upon FA loading, but may 
modulate the dynamic expansion of the ER–LD contacts under conditions in which TGs 
are actively synthesized. 
 Based on the RNA sequencing analysis, we found no evidence that ORP2-KO 
would affect the expression of the previously identified LD–ER tethering factors such as 
Insulin-sensitive fatty acid transport protein 1 (FATP1/SLC25A1) [53], diacylglycerol O-
acyltransferase 2 (DGAT2) [53], Seipin/BSCL2 [44] or Monoacylglycerol 
acyltransferase 1 (MGAT1) [25]. The RNA sequencing analysis did, however, reveal that 
ORP2-KO results in the suppression of mRNAs encoding components important for LD 
formation or growth: Perilipin 2 (-28%; adjusted p=6.05E-16) [5] and glycerol-3-
phosphate acyltransferase 4 (GPAT4; -13%; adjusted p=5.8E-5) [51]. 
 
Knock-out of ORP2 has no significant impact on the quantities of major membrane 
phospholipids and sterols 
Previous research suggests a functional role of ORP2 in cellular neutral lipid and sterol 
homeostasis [12, 15, 16, 24]. These studies were performed by employing ORP2 
overexpression or partial knock-down. Here we analysed lipid classes and their molecular 
species in HuH7 cells with a complete knock-out of ORP2, grown in serum-containing 
basal medium. Of note, the mass spectrometry platform did not cover TGs, which were 
analyzed by TLC. In addition, the cellular sterol content was manipulated by lipoprotein 
starvation, Mevastatin or LDL treatments.   
 We first analyzed ORP2-KO and control hepatocytes’ content of 
glycerophospholipids [phosphatidylcholines (PCs), lyso-PCs (LPCs), 
phosphatidylethanolamines (PEs), PE-plasmalogens (PE-Ps), phosphatidylinositols (PIs), 
-serines (PSs), and -glycerols (PGs)], ceramides, sphingomyelin, free (FC) and esterified 
cholesterol (CEs), as well as five oxysterols (25OHC, 27OHC, 7αOHC, 7βOHC and 
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7KC). The analysis did not reveal significant alterations in any of the analyzed lipid 
classes nor the oxysterol species in the ORP2-KO cells as compared to the controls 
(Supplemental Fig. S3A). Neither did the cellular sterol manipulations reveal possible 
latent effects on the cellular concentrations of FC or CEs, which might have remained 
undetected under the basal conditions (Supplemental Fig. S3B). Moreover, clustering 
analysis grouped the molecular species into nine distinct lipid clusters, none of which 
differed significantly between ORP2-KO and Cas9 cells. However, RNA sequencing of 
the ORP2-KO cells revealed significant alterations in the mRNA expression of 11 
established cholesterol homeostatic genes (Supplemental Table S2), bringing up the 
possibility that the cells chronically devoid of ORP2 may have adapted to a putative 
disturbance of cholesterol homeostasis via transcriptional changes. Upon analysis of 
individual lipid molecular species, very few differences were detectable between the 
ORP2-KO and control cells, and none of these remained significant after multiple test 
correction (Supplemental Table S3).  
 
Discussion  
We employ in this study a complete CRISPR-Cas9 knock-out of ORP2 HuH7 cells to 
comprehensively analyse the impacts of the loss of ORP2 function. The knock-out 
resulted in reductions of Akt activity, glucose uptake, glycogen synthesis, glycolysis, 
mRNAs encoding glycolytic enzymes and SREBP-1 target genes, as well as defective TG 
synthesis and storage. The defect in Akt activity was observed in both the ORP2-KO 
HuH7 hepatoma cells and in primary endothelial cells subjected to ORP2 knock-down. 
ORP2 was found to form a physical complex with key controllers of Akt activity, Cdc37 
and Hsp90, and to co-localize with Cdc37 and active Akt(Ser473) at the lamellipodia of 
both HuH7 cells and the non-cancerous HUVECs. Of note, although ORP2–VAPA 
complexes are reported to localize at ER–LD contacts [50], our quantitative EM analysis 
demonstrated that loss of ORP2 did not abolish or reduce the ER–LD membrane contact 
sites; Under the basal culture conditions even a modest increase of the total length and 
number of such contacts was observed in the KO cells. Interestingly, these parameters 
increased significantly in the Cas9 controls upon fatty acid loading, while no significant 
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increase occurred in the KO-cells, suggesting a functional role of ORP2 or its interaction 
partners in the dynamic regulation of ER–LD contacts. The knock-out did not 
significantly affect the cellular levels of membrane phospholipids, cholesterol or 
oxysterols. 
 In the present study, the discovery of ORP2 function in Akt signaling is of central 
importance. Our results show that ORP2 is physically associated with an Akt activation 
complex that contains Cdc37 and Hsp90 [3, 45]. Moreover, we demonstrate that GST-
ORP2 selectively pulls down the active, hyperphosphorylated form of Akt, and that the 
loss of ORP2 inhibits Akt signaling, consistent with the notion that ORP2 plays an 
important role in Akt activation. In this context one should also consider our earlier 
observation that ORP2 interacts in vitro with vesicles containing phosphoinositides, 
particularly PI(3,4,5)P3 [15], which plays a key role Akt activation, and with IQGAP1 
[21], which is suggested to play an important role in PI(3,4,5)P3 formation by scaffolding 
phosphoindositide kinases as well as PDK1 and Akt into functional proximity [7]. 
Importantly, our results demonstrate that ORP2-KO inhibits glucose uptake, glycogen 
synthesis, and glycolysis, effects that most likely result from the suppression of Akt 
signaling in the KO cells. Akt signaling regulates glucose uptake into hepatocytes by 
increasing the expression and plasma membrane localization of GLUT1 [2, 23], the 
mRNA of which was significantly suppressed in the ORP2-KO cells (by 30%; adjusted 
p-value 3.3E-18). Akt also regulates glucose uptake indirectly by promoting a 
concentration gradient: It induces the expression of glucokinase [18], which reduces the 
intracellular glucose concentration by phosphorylation of glucose. Thus, we envision that 
the observed impairment of glucose uptake in the ORP2-KO cells is at least in part 
explained by the suppression of Akt signaling. Moreover, by fold-change the most up-
regulated individual mRNA in ORP2-KO cells was Thioredoxin-interacting protein [21], 
which suppresses the function of GLUT1 [52]. 
 Inhibition of glycogen synthesis observed in the ORP2-KO cells is consistent with 
the reduced Akt-mediated phosphorylation of GSK-3. Glycogen synthase is regulated by 
reversible phosphorylation by GSK-3, which itself is phosphorylated and inactivated by 
Akt [9]. Importantly, activation of Akt promotes the conversion of cellular energy 
metabolism from oxidative phosphorylation to glycolysis by increasing the expression of 
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glycolytic enzymes [46]. Consistently, the reduction of active Akt in the ORP2-KO cells 
coincided in the present study with a down-regulation of the mRNAs encoding all major 
glycolytic enzymes and glycolysis measured as ECAR. Rescue of glycogen synthesis in 
the ORP2-KO cells by ORP2(mFFAT) suggested that, at least under the overexpression 
conditions, linking to the ER via VAPs is not required for the function of ORP2 in 
glucose metabolism. Consistently, the mFFAT mutant defective in VAP binding 
localized, similar to the wt ORP2, to the cell cortex where key regulation of Akt activity 
takes place (see below), and its overexpression enhanced Akt phosphorylation at Ser473. 
Similar to mFFAT, the PIP binding deficient mutant ORP2(mPIP) did enhance Akt 
phosphorylation, suggesting that PIP binding by ORP2 is not absolutely necessary for its 
function in the regulation of Akt, even though we could not obtain conclusive results on 
the ability of this mutant to rescue glycogen synthesis in the KO cells.   
 Our latest work suggested an important role of ORP2 in actin-dependent cell 
adhesion and migration [21], processes tightly connected with glycolysis: Glycolytic 
enzymes such as GAPDH and aldolase associate with F-actin, and the acute energy 
requirements in motile cell protrusions and filopodia are met by rapid local ATP 
synthesis via glycolysis [10, 33, 36]. On the other hand, PI(3,4,5)P3 and Akt orchestrate 
lamellipodia formation and cell migration by inducing actin polymerization at the leading 
edge of cells. PI(3,4,5)P3 and active Akt are found localizing in lamellipodia, and 
PI3K/Akt inhibitors disrupt lamellipodia formation and reduce cell motility [6, 20, 49]. 
Here we show that ORP2 co-localizes with active Akt(Ser473) and Cdc37 at cortactin-
positive lamellipodia, in agreement with a functional interplay of these proteins in cell 
migration. Consistently, we recently demonstrated that the ORP2-KO cells are defective 
in lamellipodia formation and migration [21]. Thus, the present observations suggest a 
new, ORP-mediated regulatory link between cellular energy metabolism and motility.  
 How does the major lipid phenotype of the ORP2-KO cells, the reduction of TGs, 
relate to the defective glucose metabolism and Akt signaling? Obviously, reduced 
glucose uptake and glycolysis are likely to be reflected in a reduced supply of precursors 
for de novo lipogenesis via the tricarboxylic acid cycle. However, the defective Akt 
signaling may contribute to the reduction of TG synthesis and storage also via another 
mechanism. Akt plays an important role in hepatic lipogenesis by enhancing transcription 
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and nuclear localization of the lipogenic transcription factor SREBP-1c [13, 39, 40, 54]. 
Thus, we envision that the present TG and glucose phenotypes may arise as a combined 
effect of Akt and SREBP-1 defects, and the Akt defect may be one factor contributing to 
the disturbance of SREBP-1 target gene expression. A model of ORP2 function in Akt 
signaling arising from the present results is presented in Fig. 7.     
 ORP2 was previously implicated in TG metabolism at ER–LD contacts [50], 
cholesterol transport [15, 19, 24], adrenocortical steroidogenesis [12], and actin-
dependent cell dynamics [21]. The present analysis is consistent with a function of the 
protein as a regulator TG synthesis and storage. Rescue of the TG synthesis defect by 
ORP2(mFFAT) and ORP2(mPIP) suggests that, at least under the overexpression 
conditions, the interactions with VAPs and PIPs are not necessary for the function of 
ORP2 in TG metabolism. The reported activities of ORP2 in cellular cholesterol 
homeostasis are not directly supported by the present data. We have previously shown 
that the loss of ORP2 does not cause significant compensatory changes in the mRNA 
levels of the 10 other ORPs expressed in HuH7 cells or their ER receptors, the VAMP-
associated proteins A and B [21]. However, the present RNA sequencing analysis 
suggests that putative distortions of cholesterol homeostasis caused by the chronic loss of 
ORP2 may have been compensated for by altered mRNA expression of a number of 
cholesterol homeostatic genes.    
 To conclude, the present study, together with our recently published work, 
identifies ORP2 as a new regulatory nexus of Akt signaling, cellular energy metabolism, 
actin cytoskeletal function, cell migration and proliferation.  
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Figure captions 
Fig. 1. ORP2-KO disturbs Akt signaling. (A) The Akt signaling components dysregulated 
in the transcriptome of ORP2-KO cells are shown in green (for up-regulation) or red (for 
down-regulation). (B) Relative mRNA expression of Akt signaling components in ORP2-
KO versus control cells (values for Cas9 controls were set at 0) analyzed by RNA 
sequencing of three replicate cultures. *p<0.05, **p<0.01, ***p<0.001 (after BH 
adjustment). 
Fig. 2. ORP2-KO inhibits Akt phosphorylation and ORP2 interacts with the Cdc37–
Hsp90–Akt effector complex. (A) Western blot analysis of Akt(Ser473) and GSK-
3β(Serλ) after 2 h serum starvation followed by an additional 8 min incubation with 100 
nM insulin added in the starvation medium. Data is shown for native HuH7 cells, Cas9 
control cells and the ORP2 knock-out cell line. (B) Western blot analysis of Akt(Ser473) 
and GSK-3β(Serλ) under basal culture conditions or after 8 min incubation with 100 nM 
insulin added in the basal medium. The ORP2 knock-out cell lines are indicated as KO1, 
KO2, and the Cas9 controls as Cas9. (C) Quantification of Akt(Ser473) phosphorylation. 
The data represents four independent western blots of independent cultures similar to that 
shown in (B). (D) Quantification of the relative GSK-3β(Serλ) phosphorylation from four 
independent estern blots of independent cultures similar to that shown in (B). (E) Western 
blot quantification of Akt(Ser473) phosphorylation in HUVECs silenced with ORP2 
specific shRNA (shORP2) or shRNA control (shCTRL) followed by an epidermal growth 
factor stimulation [(EGF) 30 ng/ml for 10 min]. The data represents three independent 
western blots of independent cultures. (F) HuH7 cells were lysed and subjected to GST-
ORP2 pull-down. Cell lysates (L) and pull-downs (PD) were analyzed by western 
blotting with anti-Cdc37, anti-Hsp90 and anti-Akt antibodies. Plain GST was used as a 
negative control. (G) GST-ORP2 pull-down of HuH7 cells treated with 5 µM Withaferin 
A. Cell lysates (L) and pull-downs (PD) were analyzed by western blotting with anti-
Cdc37, anti-Hsp90 and anti-Akt antibodies. (H) GST-ORP2 pull-down from HuH7 cell 
lysates treated with lambda protein phosphatase (Ȝ-PP). Cell lysates (L) and pull-downs 
(PD) were analyzed by western blotting with anti-Akt antibody. *p<0.05, **p<0.01, 
***p<0.001 (Student’s T-test).  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 32 
Fig. 3. ORP2 co-localizes with Akt(Ser473) and Cdc37 at lamellipodia. (A) HUVECs 
transfected with GFP-ORP2, stimulated with 100 nM insulin for 2 min and stained with 
Cdc37 [1:100 dilution (Thermo Scientific)] and Akt(Ser473) [1:25 dilution (Cell 
Signaling)] antibodies and DAPI. (B) HUVECs transfected with GFP-ORP2, stimulated 
with 100 nM insulin for 2 min and stained with Akt(Ser473) and cortactin [10 ȝg/ml 
(Merck-Millipore)] antibodies and DAPI. (A) HUVECs transfected with GFP-
ORP2(mFFAT), stimulated with 100 nM insulin for 2 min and stained with cortactin 
antibody [10 ȝg/ml (Merck-Millipore)] and DAPI. 
 
Fig. 4. ORP2-KO inhibits glucose uptake, glycogen synthesis, and glycolysis. (A) 
Quantification of [3H]-2-Deoxy-D-glucose uptake into ORP2-KO and Cas9 control cells 
during 15 min. Shown in a relative scale are averages of four independent experiments 
each performed as four replicates. (B) Quantification of D-[U-14C]-glucose incorporation 
into glycogen in ORP2-KO and control cells during 1 h. Shown in a relative scale are 
averages of three independent experiments each performed as three replicates. (C) 
Quantification of D-[U-14C]-glucose incorporation into glycogen during 1 h in ORP2-KO 
control cells infected with an empty lentiviral vector (ctrl) or a lentivirus overexpressing 
ORP2 (ORP2 oex). Shown are averages of two independent experiments both performed 
as five replicates. *p<0.05, **p<0.01, ***p<0.001 (Student’s T-test). (D) Schematic 
model of the glycolytic pathway and its enzymes down-regulated in the ORP2-KO cells. 
(E) Relative expression of glycolytic genes in ORP2-KO versus control cells (Cas9 
controls were set at 1) analyzed by RNA sequencing of four replicate cultures. *p<0.05, 
**p<0.01, ***p<0.001 (after BH adjustment). (F) Extracellular acidification rate (ECAR) 
after glucose, Oligomycin and 2-deoxy-D-glucose (2-DG) injections of control and 
ORP2-KO cells measured with a Seahorse XFe96 analyzer in four independent 
measurements each as 12 replicates. (G) Calculation of the average glycolysis rate from 
the measurements shown in (F) by reducing the non-glycolytic acidification from the 
maximum ECAR before Oligomycin injection; *p<0.05, **p<0.01, ***p<0.001 
(Student’s T-test). Abbreviations: PGK1, phosphoglycerate kinase 1; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; ALDOA, fructose-bisphosphate aldolase A; 
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ENO, enolase; PKM, pyruvate kinase; PGAM1, phosphoglycerate mutase 1; TPI1, triose 
phosphate isomerase 1; PFKFB, 6-phosphofructo-2-kinase; GP1, glucose-6-phosphate 
isomerase. 
Fig. 5. ORP2 knock-out reduces the TG content and modifies the expression of TG 
metabolic genes of hepatoma cells. (A) ORP2-KO and control cells’ TG content was 
assessed by thin-layer chromatography. Shown is mean of five replicate cultures. (B) TG 
synthesis was measured in ORP2-KO and control cells by [3H]-oleic acid labeling for 3 h. 
Shown is mean of two independent experiments each performed as four replicates. (C) 
Quantification of [3H]-palmitic acid uptake into ORP2-KO and control cells during 15 
min. Shown in a relative scale are averages of two independent experiments each 
performed as four replicates. (D) Quantification of TG synthesis with [3H]-oleic acid 
labeling for 3 h in ORP2-KO control cells infected with an empty lentiviral vector (ctrl) 
or a lentivirus overexpressing ORP2 (ORP2 oex). Shown are averages of two 
independent experiments both performed as five replicates. *p<0.05, **p<0.01, 
***p<0.001 (Student’s T-test). (E) Relative mRNA expression of SREBP-1 and its target 
genes in ORP2-KO versus control cells (values for Cas9 controls were set at 1) analyzed 
by RNA sequencing of four replicate cultures. (F) Relative gene expression of TG 
metabolic genes in ORP2-KO cells versus control cells (Cas9 controls were set at 1) 
analyzed by RNA sequencing of four replicate cultures. The statistical analysis of the 
RNA sequencing data is specified in Material and methods, section ‘RNA sequencing 
and pathway analysis’. *p<0.05, **p<0.01, ***p<0.001 (after BH adjustment).  
Fig. 6. ORP2-KO does not reduce ER–LD contact sites but affects their dynamic 
expansion after fatty acid (FA) loading. ORP2-KO and control cells were either grown in 
basal culture medium or loaded for 3 h with FA as described in Materials and Methods. 
(A) TEM micrograph from KO2 loaded sample showing modeled LDs  (depicted in 
purple) and the ER (depicted in yellow) that is in close vicinity to intact LDs. The ER-LD 
contact sites that are within 30 nm distance are shown with green lines. Scale bar 500 nm. 
(B) Total LD area per cell. (C) Total length of ER–LD contacts per cell. The data 
represents mean r SEM from 16–32 cells, with 4 images from each analyzed; */#p<0.05, 
**/##p<0.01, ***/###p<0.001 (Student’s T-test); * indicates significant difference 
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between unloaded and loaded cells, and # indicates significant difference between Cas9 
ctrl and ORP2-KO cells. 
Fig. 7. A schematic model of ORP2 function in Akt signaling. Akt signaling is activated 
by extracellular growth factors (e.g. insulin), which binds to plasma membrane (PM) 
growth factor receptors (GFR) resulting in activation of intracellular PI3-kinase (PI3K). 
PI3K phosphorylates PIP2 to PIP3, triggering a PM recruitment of phosphoinositide-
dependent kinase-1 (PDK1) and Akt. The protein kinases (PI3K/PDK1/Akt) are 
scaffolded by IQGAP1 which interacts with ORP2. At PM, Akt interacts with its effector 
complex Hsp90-Cdc37-ORP2 and is phosphorylated by PDK1. Active Akt regulates the 
activity of several downstream target molecules (e.g. GSK3), resulting in increased 
uptake of glucose, glycogen synthesis, glycolysis, lipogenesis via SREBP-1 and 
migration of cells. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1 Click here to download Figure Figure1.tif 
Figure 2 Click here to download Figure Figure2.tif 
Figure 3 Click here to download Figure Figure3.tif 
Figure 4 Click here to download Figure Figure4.tif 
Figure 5 Click here to download Figure Figure5.tif 
Figure 6 Click here to download Figure Figure6.tif 
Figure 7 Click here to download Figure Figure7.tif 
  
Supplemental method description and captions for thesupplemental figures
Click here to access/download
Supplementary Material
Kentala et al_Supplemental materials.docx
  
Supplementary Table S1
Click here to access/download
Supplementary Material
Supplemental Table S1.docx
  
Supplementary Table S2
Click here to access/download
Supplementary Material
Supplemental Table S2.docx
  
Supplementary Table S3
Click here to access/download
Supplementary Material
Supplemental Table S3.docx
  
Supplemental Figure S1
Click here to access/download
Supplementary Material
FigureS1.tif
  
Supplemental Figure S2
Click here to access/download
Supplementary Material
FigureS2.tif
  
Supplemental Figure S3
Click here to access/download
Supplementary Material
FigureS3.tif
